Biofrontera (NASDAQ:BFRI) Releases Earnings Results, Beats Expectations By $0.01 EPS

Biofrontera (NASDAQ:BFRI) released its quarterly earnings data on Wednesday. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.01, Zacks reports. Biofrontera had a negative return on equity of 1,104.09% and a negative net margin of 42.34%.The business had revenue of $6.99 million for the quarter, compared to analysts’ expectations of $7.00 million.

Biofrontera Stock Performance

Shares of BFRI opened at $0.97 on Thursday. The stock has a market capitalization of $11.34 million, a price-to-earnings ratio of -0.51 and a beta of 0.55. Biofrontera has a 12 month low of $0.54 and a 12 month high of $1.87. The firm has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $0.85. The company has a current ratio of 0.96, a quick ratio of 0.75 and a debt-to-equity ratio of 8.99.

Institutional Trading of Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. boosted its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera accounts for about 0.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 27th biggest holding. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 10.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biofrontera in a report on Thursday, October 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Biofrontera currently has an average rating of “Hold” and a consensus target price of $2.75.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.